After much delay, Novartis has finally won a key FDA go-ahead for Pluvicto, opening up the radioligand therapy to a much ...

Even as Novartis takes home a partial win in court tied to its key blockbuster Entresto, the Swiss drugmaker continues to ...

Docquity, Southeast Asia's largest network of healthcare professionals (HCPs), and global healthcare company Novartis announce a multi-year partnership in Malaysia to address the rise of retinal ...

Goldman Sachs estimates that AI drug discovery and breakthroughs like gene editing will add 0.5% to 2.5% to the U.S. gross ...

The notice comes three months after the pharmaceutical giant said it would eliminate 139 jobs at the location between February and August.

omnichannel commercial capabilities under its Awareness to Advocacy (A2A) Program, Novartis enhances retinal health education for thousands of ophthalmologists and medical retina doctors across the ...

Pharmaceutical company Novartis is laying off more than 400 US employees who report to its East Hanover facility as part of a ...

Blueprint Medicines' strong pipeline and Ayvakit growth make it promising. Read why BPMC stock is rated "Hold" due to high ...

Novartis signed on for its space at the Fifth Avenue building between West 39th and West 40th streets in January 2023, as Commercial Observer previously reported. It represented the company’s first ...

Stanway (pictured) said commercial concerns were the most likely reason for Novartis to get cold feet on the project. He told pharmaphorum in an interview: “Some commentators say they may be ...